SCHEMBL4415280

SCHEMBL4415280

O=C(c1ccccc1)c1sc(S(=O)(=O)Cl)nc1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 7/20 0.56
ADORA2B P29275 2/20 0.56
NPSR1 Q6W5P4 6/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
HTT P42858 4/20 0.52
ALDH1A1 P00352 3/20 0.52
LMNA P02545 3/20 0.52
ALOX5 P09917 3/20 0.52
MAPT P10636 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
ADORA1 P30542 6/20 0.52
ADORA2A P29274 3/20 0.52
RORC P51449 1/20 0.47
RORB Q92753 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242397 0.76 ADORA3 (0.61) ADORA3ADORA2BNPSR1SMN1; SMN2HTT
SCHEMBL165773 0.76 ADORA3 (0.61) ADORA3ADORA2BNPSR1SMN1; SMN2HTT
SCHEMBL4425292 0.74 KDM1A (0.47) NPSR1SMN1; SMN2ALDH1A1LMNAALOX5
SCHEMBL3456228 0.74 ADORA2B (0.62) ADORA3ADORA2BNPSR1SMN1; SMN2HTT
SCHEMBL5330562 0.71 CDC7 (0.51) ADORA3ADORA2BNPSR1SMN1; SMN2HTT
SCHEMBL178218 0.70 ADORA3 (0.60) ADORA3ADORA2BNPSR1SMN1; SMN2HTT
SCHEMBL257616 0.70 ADORA3 (0.64) ADORA3ADORA2BNPSR1SMN1; SMN2ALDH1A1
SCHEMBL27653975 0.68 ADORA3 (0.51) ADORA3ADORA2BNPSR1SMN1; SMN2HTT
SCHEMBL1249616 0.68 ADORA3 (0.51) ADORA3ADORA2BNPSR1SMN1; SMN2HTT
SCHEMBL10092883 0.68 RORB (0.67) ADORA3ADORA2BALDH1A1ADORA1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1829714-B Pna monomer and precursor PANAGENE INC 2012-05-30 CN disclosed
EP-1651642-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-11-04 EP disclosed
US-7211668-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2007-05-01 US disclosed
EP-1651642-A4 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2006-11-29 EP disclosed
CN-1829714-A PNA monomer and precursor PANAGENE INC (KR) 2006-09-06 CN disclosed
EP-1651642-A1 PNA MONOMER AND PRECURSOR Panagene Inc. (KR) 2006-05-03 EP disclosed
US-20050026930-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-02-03 US disclosed
WO-2005009998-A1 PNA MONOMER AND PRECURSOR PANAGENE INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026930-A1 PNA monomer and precursor RNGTT, POLL, NSUN3 ADORA3 127/4885ADORA2B 173/4885NPSR1 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.